News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Convergence Pharmaceuticals Announces Start of Phase II Study for CNV1014802 for Trigeminal Neuralgia


3/19/2012 9:06:50 AM

CAMBRIDGE, England, March 19, 2012 /PRNewswire/ --

Novel sodium channel blocker with excellent pharmacokinetic and safety profile could fill treatment gap for severe pain condition

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started. CNV1014802 is novel small molecule, state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel.

TN is a very severe form of facial pain that is experienced in short bursts or attacks. The International Association for the Study of Pain (IASP) defines TN as sudden, severe, brief, stabbing, recurrent episodes of pain usually on one side of the face and can be provoked by light touch. The pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth, face and the front of the scalp.

TN currently affects approximately 50,000 people in the USA alone. The majority of people affected are over 50 years of age, however many cases have been reported in young adults. TN is more prevalent in women than men, and for most sufferers, the condition is progressive and worsens over time. TN is commonly misdiagnosed and to date there is no guaranteed cure for the condition. Current therapies are centred on sodium channel blockers such as carbamazepine or oxcarbazepine as first-line treatments. However, these agents although providing relief, are often poorly tolerated, and require lengthy dose escalation, resulting in sub-optimal efficacy.

The Phase II trial is a randomised, double-blind, placebo-controlled withdrawal study designed to evaluate the efficacy and safety of orally administered CNV1014802 in patients with TN. The trial will run in six countries and the first results are expected in mid 2013.

Commenting on the announcement Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, said: "We are delighted to announce the start of this Phase II trial in trigeminal neuralgia, our second clinical trial of CNV1014802, following a Phase II proof of concept study initiated in July 2011 for treating pain associated with lumbosacral radiculopathy (LSR). CNV1014802 has already demonstrated an excellent pharmacokinetic and safety profile in over 160 healthy volunteers in Phase I trials. TN is a very debilitating disorder and we are confident that CNV1014802 will help fill the desperate need for innovative new treatments. We look forward to reporting results in 2013."

Prof Joanna Zakrzewska, Consultant and Facial Pain Unit Lead, Eastman Dental Hospital, UCLH NHS Foundation Trust, said: "It is very exciting to have a potential new drug to use in TN as this rare condition has to date had to rely on use of drugs previously developed for other purposes. Convergence has taken the bold step of testing it in a randomised control trial so that high quality evidence will be forthcoming very quickly. Designing studies for pain conditions where it would be unethical to use a placebo has been a challenge and we hope that this design will enable us to recruit the patients so that we can extend our drug therapies, so desperately needed."

For more information on Trigeminal Neuralgia (TN), please visit the Trigeminal Neuraligia Association (TNA) website: http://www.tna.org.uk/

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees, with an estimated 116 million American adults affected by chronic pain - more than heart disease, cancer and diabetes combined.[1] Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, addressing acute and chronic pain, is on the rise.

According to recent research the global pain management market is to reach US$60 billion by 2015.[2]

References:

  1. Report by the Institute of Medicine, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, June 2011
  2. Global Industry Analysts Inc. 2010, Pain Management: A Global Strategic Business Report. http://www.strategyr.com/Pain_Management_Market_Report.asp

About Convergence Pharmaceuticals

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, led by CEO Clive Dix, was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline ("GSK"). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels. Convergence Pharmaceuticals is well funded and raised $35.4 million in Series A financing from a syndicate of leading European and US financial institutions. For more information please go to the Company's website at http://www.convergencepharma.com.

For more information about Convergence Pharmaceuticals, please contact:
Convergence Pharmaceuticals
Dr Clive Dix, Chief Executive Officer
Dr Simon Tate, Chief Scientific Officer
T: +44(0)1223-755-501
E: info@convergencepharma.com

M:Communications
Mary Clark / Amber Bielecka / Hollie Vile
T: +44(0)20-7920-2330
E: convergence@mcomgroup.com

SOURCE Convergence Pharmaceuticals Ltd


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES